Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
602-02-009 ISMRM Abstract

Aggressive Tumor Fraction as a Biomarker for Prostate Cancer Progression: Risk Assessment of Active Surveillance Patients

Primary: Analysis Methods - Classification and Prediction
Secondary: Body - Prostate
602-02-009 · Prostate MRI: Methodological Developments · Thursday, 14 May, 1:40 PM–3:30 PM · Hall 1B
Keywords: Prostate cancer Prostate MRI Survival analysis Clinical trials Cancer probability prediction
Accepted
Ahmad Algohary1, Veronica Wallaengen1,2, Adrian L Breto1, Noah C Lowry1, Arpita Dutta 1, Nicolas T Stoll1, Sandra M Gaston1, Alan Pollack1, Sanoj Punnen2, Radka Stoyanova1
1Radiation Oncology, University of Miami, Miami, United States of America
2Urology, University of Miami, Miami, United States of America
Presenting Author: Arpita Dutta

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022;20(12):1288-98. Epub 2022/12/13. doi: 10.6004/jnccn.2022.0063. PubMed PMID: 36509074. [doi] [pmid]
2. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112(12):2664-70. Epub 2008/04/25. doi: 10.1002/cncr.23502. PubMed PMID: 18433013. [doi] [pmid]
3. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. PubMed PMID: 26427566. [doi] [pmid]
4. Stoyanova R, Chinea F, Kwon D, Reis IM, Tschudi Y, Parra NA, Breto AL, Padgett KR, Dal Pra A, Abramowitz MC, Kryvenko ON, Punnen S, Pollack A. An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. Int J Radiat Oncol Biol Phys. 2018;102(4):821-9. Epub 2018/06/17. doi: 10.1016/j.ijrobp.2018.06.003. PubMed PMID: 29908220; PMCID: PMC6245650. [doi] [pmid]
5. Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, Pollack A. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer. 2013;119(5):1080-8. Epub 2012/10/26. doi: 10.1002/cncr.27857. PubMed PMID: 23096533; PMCID: PMC4347814. [doi] [pmid]
6. Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA, Cornud F, Choyke PL. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol. 2016;69(1):41-9. Epub 2015/09/12. doi: 10.1016/j.eururo.2015.08.038. PubMed PMID: 26361169; PMCID: PMC6364687. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/602-02-009